Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The only curative therapy for thalassemia major remains the replacement of the defective
erythropoiesis by allogeneic hematopoietic stem cell transplantation(allo-HSCT). We conduct a
prospective multicenter study to evaluate the efficacy of allo-HSCT in the treatment of
thalassemia major.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Guangxi Medical University
Collaborators:
Fourth Affiliated Hospital of Guangxi Medical University Hainan General Hospital Liuzhou General Hospital Peking University People's Hospital Ruijin Hospital The 923th Hospital of People's Liberation Army The Affiliated Hospital Of Guizhou Medical University The First People's Hospital of Yunnan